Boldenone Undecylenate

Veterinary-equine AAS — testosterone with an added 1,2-double bond, esterified to undecylenate for ~14-day half-life. Mild aromatization, mild DHT conversion, strong RBC-mass elevation (signature side effect: polycythemia), B-tier body-comp evidence, real-but-moderate HPG suppression. For Dylan: SKIP-AT-20 by same-family AAS logic — HPG suppression at 20 risks long-term shutdown of a still-maturing axis, lipid + polycythemia + BP signals are real, brain/MMA priorities sit above aesthetic/mass goals, and gray-market veterinary sourcing carries QC and contamination risk. Revisit at 28-30+ only if a competitive aesthetic / mass goal becomes primary AND with full baseline + monitoring framework.

Boldenone is testosterone with one structural modification: the addition of a double bond between carbons 1 and 2 of the steroid A-ring (Δ1-testosterone). The undecylenate ester is hung off the 17β-OH for slow release.

The 1,2-double bond does three things:

1. Reduces aromatization to estradiol (~50% of testosterone's rate). The Δ1 modification interferes with aromatase's positioning of the A-ring. Boldenone still aromatizes — to 1-dehydroestradiol (also called Δ1-estradiol or boldenone-aromatized) — but at roughly half the rate testosterone does. Practical effect: less estrogenic burden per mg than testosterone, so less gynecomastia risk, less water retention, but estrogen control is still part of any honest protocol.

2. Reduces 5α-reduction to DHT. Boldenone is a poor substrate for 5α-reductase. Conversion to 1-dehydro-DHT (1,2-dehydro-DHT) — a much weaker androgen than DHT itself — happens at low rates. Practical effect: less DHT-pathway side effects (less acne, less aggressive androgenic alopecia, less prostate hyperplasia) per mg than testosterone. Note that 1-dehydro-DHT is itself only weakly active; DHT-target tissues (skin, scalp, prostate) get less stimulation overall.

3. Slightly improves anabolic-to-androgenic ratio. Boldenone is rated at roughly 100:50 anabolic:androgenic (vs. testosterone at 100:100). This is the canonical claim; it derives from rat ventral prostate / levator ani assays from the 1950s-1960s and should be treated as approximate. The practical signal in human use is consistent: per-mg, less androgenic side effect than testosterone, similar-to-slightly-less anabolic effect.

The undecylenate ester is an 11-carbon unsaturated fatty acid (C10H19COOH, the acid form of undecylenic acid). Esterified to the 17β-OH, it makes boldenone:

• Lipophilic — slow release from intramuscular oil depot
• Long-acting — terminal half-life ~14 days; clinical effect persists 2-3+ weeks per dose
• Slow-onset — peak serum levels at 3-4 days post-injection, full steady-state takes 4-6 weeks of weekly dosing

RBC mass elevation (the signature side effect):

Boldenone is among the strongest erythropoiesis-stimulating AAS in the class. Mechanism is multifactorial:

• Direct stimulation of renal EPO production (AR-mediated)
• Increased iron utilization and reticulocyte mobilization
• Possibly enhanced bone-marrow sensitivity to EPO

Clinical pattern: hematocrit creep starts within 4-8 weeks, can reach 55-58% (vs. baseline ~42-46% in healthy young males) at typical "physique enhancement" doses (300-600 mg/week). This is the single most monitor-relevant side effect — not the most dangerous theoretically, but the most commonly clinically actionable one. Therapeutic phlebotomy is the standard intervention.

Appetite stimulation:

Boldenone has a reputation for moderate appetite stimulation. Mechanism is incompletely characterized; likely central/hypothalamic AR engagement and possibly indirect ghrelin or leptin axis effects. Plain English: many users report increased hunger 4-6 weeks into use; this is part of the value proposition for users in mass / lean-bulking contexts. Irrelevant for Dylan (already hits protein, no mass goal).

Why the verdict is SKIP-AT-20 even though boldenone is mechanistically "milder" than testosterone:

The mildness vs. testosterone applies to the aromatization and DHT pathways. The HPG-axis suppression — the part that matters for a 20-year-old whose hypothalamic-pituitary-gonadal axis is still maturing — is not mild. AR agonism downstream of any AAS suppresses GnRH → LH/FSH → testicular T production via standard negative feedback. Boldenone does this. Long-acting esters do this for the duration of detectable serum levels (weeks after final dose). Anyone running EQ at "physique" doses for a 12-16 week cycle has months of HPG suppression to recover from. At 20, with no compelling reason for the cycle, this is a permanent-fertility / permanent-HPG-injury risk that swamps any body-comp gain.